MedDataX Logo

PAncreatic Disease Cohort of TOuLouse

NCT ID: NCT05824403

Last Updated: 2023-12-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-11-28

Study Completion Date

2027-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a prospective cohort dedicated to pancreatic diseases excluding cancer. The aim is to develop positive or differential diagnostic tools between benign potentially malignant or malignant pancreatic pathologies. During this study the investigators collect data and biological samples to support research project.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This collection focuses on pathology of the pancreas requiring specific investigations or management for diagnosis or treatment. Pancreatic pathologies can be classified as malignant, potentially malignant or benign tumors. These can be solid or cystic. There is an inflammatory attack on the pancreas, generating acute pancreatitis in the acute period, if the inflammatory manifestations persist, chronic pancreatitis will develop. Some lesions may be at risk of malignancy during their evolution, it is therefore necessary to improve the performance of monitoring and diagnostic tools in order to adapt the management of patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreatic Diseases

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Pancreatic cyst Acute pancreatitis chronic pancreatitis Intra Pancreatic Mucinous Neoplasia diagnosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with inflammatory or cystic exocrine pancreatic pathology
* Patient able to read and understand the information leaflet
* Patients who have agreed to participate in the study and have signed the free and informed consent
* Patients affiliated to a social security system (including AME)

Exclusion Criteria

* Patient with pancreatic cancer pathology
* Patients with active cancer, whatever the origin
* Pregnant or breastfeeding patients
* Patients under legal protection, guardianship or trusteeship
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Toulouse

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Barbara BOURNET, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Toulouse

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Rangueil hospital

Toulouse, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Barbara BOURNET, MD

Role: CONTACT

Phone: 0561323235

Email: [email protected]

Cindy CANIVET

Role: CONTACT

Phone: 05 61 32 20 48

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Barbara BOURNET, MD

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Bardol T, Dujon AM, Taly V, Dunyach-Remy C, Lavigne JP, Costa-Silva B, Kurma K, Eslami-S Z, Cayrefourcq L, Canivet C, Muscari F, Bournet B, Alix-Panabieres C. Early detection of pancreatic cancer by liquid biopsy "PANLIPSY": a french nation-wide study project. BMC Cancer. 2024 Jun 10;24(1):709. doi: 10.1186/s12885-024-12463-8.

Reference Type DERIVED
PMID: 38853244 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RC31/22/0530

Identifier Type: -

Identifier Source: org_study_id